Core Viewpoint - The company Rui Feng Gao Cai (瑞丰高材) is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading involving its board secretary, Zhao Ziyang, although the investigation does not pertain to the company's stock trading or operations [2]. Group 1: Company Background - Rui Feng Gao Cai's main businesses include plastic additives and biodegradable materials, with key products such as ACR processing aids and impact modifiers [5]. - Zhao Ziyang has been with the company for 16 years, holding various positions before becoming the board secretary [3]. Group 2: Financial Performance - In 2024, the company reported revenue of 2 billion yuan, a year-on-year increase of 12.7%, but a net profit of 22.08 million yuan, a decline of 74.1% [5]. - For Q1 2025, revenue was 474 million yuan, down 2.91% year-on-year, with a net profit of 5.28 million yuan, a decrease of 45.96% [5]. Group 3: Stock Price Volatility - The company's stock price experienced significant fluctuations, rising over 220% from a low of 5.02 yuan per share in February 2024 to a high of 16.11 yuan in May 2024 [6]. - The stock price later fell and then rose again, indicating investor interest in the company's new business ventures [6]. Group 4: New Business Developments - The company is focusing on new technologies, including synthetic biology, black phosphorus materials, and solid-state battery adhesives, with ongoing projects in these areas [6]. - However, the revenue from these new businesses is expected to be minimal in the short term, with projected sales for black phosphorus products not exceeding 50,000 yuan and synthetic biological materials not exceeding 100,000 yuan in 2024 [7]. Group 5: Compliance and Governance Issues - The investigation into Zhao Ziyang highlights potential issues with the company's internal control mechanisms and compliance culture, suggesting a need for improvements in governance and oversight [4].

Core Viewpoint - New Hope Dairy is focusing on a "fresh strategy" to drive growth and innovation in the dairy industry, emphasizing high-end products, market penetration, and user engagement [2][3]. Group 1: Company Strategy - The company aims to innovate through a dual-engine approach involving product and channel development, targeting high-end and deep market segments [2][4]. - New Hope Dairy's "fresh strategy" includes a comprehensive framework of "eight fresh" dimensions, covering fresh sourcing, production, orders, delivery, and consumer engagement [4]. - The company has established a strategic partnership with the Norwegian Gene Cow Breeding Association to enhance its product offerings with Norwegian Red Cow milk [4]. Group 2: Financial Performance - In 2024, New Hope Dairy's net profit attributable to shareholders is projected to grow by 24.8%, with a net profit margin of 5.15% [3]. - The company's high-end fresh milk business has seen double-digit growth, with the "24-hour" mid-to-high-end product series revenue increasing by over 15% [3]. Group 3: Market Expansion - New Hope Dairy is pursuing a three-pronged growth strategy, which includes high-end national development, localized market penetration through the "Cool Mountain Snow" brand, and international expansion [6][7]. - The "Cool Mountain Snow" brand has achieved a 75% market share in its local area, demonstrating effective market penetration strategies [6]. Group 4: Innovation and Sustainability - The company is committed to technological and channel innovation to ensure freshness and break through homogenized competition [4][7]. - New Hope Dairy emphasizes the importance of environmental friendliness and health in its product offerings, aiming to create a sustainable and enjoyable lifestyle for consumers [7].

Group 1: Market Overview - The total trading volume in the Shanghai and Shenzhen markets reached 1.26 trillion yuan, a decrease of 159.9 billion yuan compared to the previous trading day [2] - Sectors such as rare earth permanent magnets, gaming, automotive parts, and securities saw significant gains, while sectors like controllable nuclear fusion, biological vaccines, communication services, and beverage manufacturing experienced declines [2] Group 2: Notable Stocks - Yiming Pharmaceutical (002826) achieved a limit-up of 9.99%, marking its sixth consecutive trading day of gains, driven by a change in control and diabetes generic drugs [1][2] - Wukuyatu (002878) rose by 9.98%, with a total of five gains over nine days, attributed to digital cultural assets and IP culture [1][2] - Aonlikang (002940) also increased by 9.98%, with seven gains over the past seven days, focusing on innovative drugs and generics [1][2] - Jinying Co. (600232) hit a limit-up of 10.00%, supported by injection molding machines, textile machinery, and lithium batteries, achieving four consecutive gains [1][2] - Chutianlong (003040) saw a limit-up of 10.03%, driven by digital RMB and cross-border payments, with three gains over four days [1][2] Group 3: Institutional Activity - The top three net purchases on the Dragon and Tiger list were from Limin Co. (002734), Chutianlong (003040), and Aonlikang (002940), with net purchases of 166 million yuan, 149 million yuan, and 91.69 million yuan respectively [4] - The top three net sales were from Lianhua Technology (002250), Baili Electric (600468), and Zhi De Co. (603333), with net sales of 289 million yuan, 209 million yuan, and 169 million yuan respectively [5] Group 4: Company Highlights - Limin Co. reported a revenue of 1.211 billion yuan for Q1 2025, a year-on-year increase of 22.28%, with a net profit of 108 million yuan, marking a turnaround due to strong demand and price increases [10] - Aonlikang focuses on innovative drugs and generics, with a recent trading volume of 1.393 billion yuan and a net institutional purchase of 235 million yuan [11][15] - Chutianlong is actively developing a digital RMB smart contract platform, collaborating with multiple organizations to provide integrated solutions for various scenarios [18]

珀莱雅 603605.SH 公司研究 | 动态跟踪 站在新发展阶段的多品牌美妆龙头 核心观点 盈利预测与投资建议 ⚫ 我们维持对公司的盈利预测，预计公司 2025-2027 年每股收益分别为 4.56、5.36 和 6.06 元，DCF 目标估值 112.78 元，维持"买入"评级。 风险提示：行业竞争加剧、终端消费需求减弱、新品拓展不及预期等 行业竞争加剧、终端消费需求减弱、新品拓展不及预期等 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 8,905 | 10,778 | 12,339 | 14,072 | 15,577 | | 同比增长 (%) | 39.5% | 21.0% | 14.5% | 14.0% | 10.7% | | 营业利润(百万元) | 1,503 | 1,890 | 2,200 | 2,584 | 2,923 | | 同比增长 (%) | 42.1% | 25.8% | 16.4% | 17.5% | 13.1% | | 归 ...

为助力生物基和生物制造产业高质量发展！ 最新5月期出炉，并已经通过邮箱发送至DT新材料新老客户，记得点击查看喔！ 同时，欢迎行业上下游同仁 免费领取 ！ 领取方式 ① ： 扫码下方二维码，提交信息后，即可下载报告（2份报告可一同下载）； 领取方式 ② ： www.bio-basedlink.net ，或点击文末 → 阅读原文 ↓ 领取方式 ③ ： 如果您是DT会员，请联系DT助手领取； ↓↓↓ 《生物基产业月度报告》 2025年5月（总第26期） 生物基产业月度报告 DT产业研究院 推出 《全球生物基产业月度报告》 系列 5分钟，掌握全球生物基产业最新情报和大厂动态，洞悉趋势，发现商机！ Bio-based Industries Monthly Review Policy Release Capital Events Industry Dynamics Scientific Research Progress 总第26期 全球生物基和生物制造产业服务平台 https://www.bio-basedlink.net/ 皮德泰中研信息科技 ■ 新加料 目录 | 1. 政策发布 | | --- | | 1.1 国内 ...

# SynBio团队 | 中科院苏州医工所马富强 在人工生命体精准编程的"黄金时代"，合成生物学作为融合工程学、计算机科学与分子生物学的交叉学科， 正通过"设计-构建-测试"的循环模式重塑生物制造范式。这一领域不仅被列为全球科技竞争的战略高地，更在 医药研发、碳中和、农业升级等关乎国计民生的赛道上展现出颠覆性潜力。 其核心突破点聚焦 三大支柱 ： 三大支柱技术如同精密咬合的齿轮，共同决定了细胞合成工厂的效率 。 【SynBioCon】 获 悉，近日， 苏州医工所马富强研究团队 围绕上述合成生物学三大支柱技术开展了系统工 作： 图2. 利用深度学习辅助生成新型启动子的两种方法 ： 左 图 ， 通过对现有启动子引入突变或随机生成新序列 来创建新的序列。这些新生成的序列通过启动子识别模型进行筛选，以验证其功能 ；右 图 ， 使用扩散模型 或生成对抗网络（GANs）来生成新的启动子。扩散模型通过添加高斯噪声逐步生成启动子序列。GANs 由生 成器和判别器组成，生成器负责生成假样本，而判别器用于区分真实样本和生成的假样本。通过训练过程不 断优化生成器的性能，使其能够生成更逼真的启动子序列。 工作1 ： 新型酶资源 的 ...

#全球政策进展 | 工信部 【SynBioCon】 获 悉，6月11日， 工业和信息化部办公厅 、 国家发展改革委办公厅 发布《关于开展生物 制造中试能力建设平台培育工作的通知》(下称：《通知》)提到，培育 食品及添加剂、生物制药、化妆品、 化工、能源、酶制剂等 重点产品领域的 三大类型 中试平台。 其中提出，立足产业现状和发展需求，布局相适应的中试能力和服务体系，鼓励国家级实验室、国家级科 技创新平台打造中试能力建设平台。坚持市场主导、需求引导。围绕技术研发、成果转移和商业化应用各 环节重大需求和典型场景开展针对性培育，鼓励中试平台按照市场化原则开展有偿服务并实现稳定运营。 坚持规范引领、安全可靠。完善中试装备标准体系和中试服务规范流程，增强平台数据安全、生物安全保 障能力。 到2027年，力争培育中试能力建设平台20个以上，服务企业数量超过200家，孵化产品400个以 上，有力支撑创新成果的"小试验证—中试扩大—产业化应用" 。 通知提出，立足生物制造产业化现状和技术发展需求，聚焦生物制造各领域中试环节的短板和痛点，根据 技术工艺装备特点，培育 食品及添加剂、生物制药、化妆品、化工、能源、酶制剂等重点产品 ...

| 上榜热股 | 实时涨跌幅 | 买/卖家数 | | | --- | --- | --- | --- | | 利民股份 002734.SZ | +10.02% | 3/2 | +1 | | 昂利康 002940.SZ | +9.98% | 4/2 | +1 | | 3日 | | | | 利民股份 龙虎榜机构热股 今天机构龙虎榜上榜30只个股，净买入9只，净卖出21只。当日机构买入最多的个股前三位是：利民股份（1.93亿）、昂利康（3日1.7亿）、澳洋健康（1356 万）。 龙虎榜显示，5家机构净买入1.93亿。 国联民生证券表示，公司同步推进"AI+农药"与合成生物学双轮驱动战略，通过德彦智创平台整合AI算法与生物合成技术，叠加与全球农化巨头的商业化协 同，有望进一步强化其在绿色农药创制领域的先发优势。短期来看，受益于阿维菌素、甲维盐、百菌清、代森锰锌等主要产品价格上涨，公司盈利能力有望 持续修复。 龙虎榜知名游资 个股龙虎榜 二、盲盒、IP经济 催化方面，泡泡玛特6月11日收涨4.25%，再创历史新高。 青木科技 个股龙虎榜 一、汽车零部件 近日，中国一汽、东风汽车、赛力斯集团、广州汽车集团、吉利汽车集团、 ...

Core Viewpoint - The research team has developed a portable microbial fuel cell using 3D printed living hydrogels, which has significant potential for applications in medical devices and sustainable energy supply [1][2]. Group 1: Technology and Innovation - The microbial fuel cell integrates bioelectrical stimulation devices to achieve precise regulation of electrophysiology and blood pressure, showcasing its application potential in disease treatment [1]. - The innovative 3D printed living hydrogel material, based on Shewanella bacteria, allows for the construction of complex structures and enhances mechanical strength and conductivity [2]. - The micro fuel cell, with a diameter of only 20mm, can output a stable voltage of 450mV and complete up to 10 cycles of "self-charging-discharge" [2]. Group 2: Performance and Advantages - The microbial fuel cell demonstrates a high bacterial survival rate of 97% after energy cycles, maintaining over 90% survival even after 100 hours of continuous operation, indicating excellent biocompatibility [2]. - The device avoids the use of scarce metals and toxic electrolytes found in traditional batteries, presenting significant environmental advantages [2]. - Although the energy density is currently at 0.008 watt-hours per liter and power density at 8.31 microwatts per square centimeter, it is sufficient for low-power devices [2]. Group 3: Application and Future Directions - The research targets instantaneous neural stimulation in precision medicine, with successful results in rat experiments showing significant blood pressure reduction [3][4]. - Future plans include developing implantable bio-batteries powered by human blood glucose, aiming for self-sustaining medical devices [4]. - The research reflects a cross-disciplinary innovation between synthetic biology and materials science, with promising applications in medical implants and environmental monitoring sensors [4].

在此之前，类似的基因调控技术仅限于在细菌等单细胞生物中实现，而在复杂的多细胞植物中应用这一 技术，则面临更大挑战。因为植物不仅具有根、茎、叶等不同组织结构，还包含不同的营养和生殖器 官，发育过程更加复杂。 为实现这一目标，团队首先合成了相关的植物DNA片段，并围绕其中两个关键基因构建了一个潜在的 遗传"切换系统"。他们结合数学建模方法，在计算机中模拟多种可能的组合，筛选出最有效的设计方 案。随后，研究人员将选定的DNA序列导入植物体内，并在12天内持续监测其变化，以定量评估基因 表达的调控效果。 美国科罗拉多州立大学团队成功合成出一种"基因开关"，首次实现了灵活地开启或关闭成熟植物中的关 键遗传特性。该成果发表在最新美国化学会旗下的《ACS合成生物学》杂志上，为未来按需设计的智能 农业打下基础。 这项研究由跨学科团队完成，是合成生物学领域具有里程碑意义的重要进展。团队通过设计和构建新的 DNA片段，并将其植入生物体内，使生物体具备类似电子电路的功能。这种"基因开关"就像控制电灯 开关一样，在外部信号的作用下，可以精确地打开或关闭特定基因的表达。 该研究首次实现了对植物基因功能的可预测、可编程调控，为未来按需设 ...